These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 26699098)

  • 1. Growth Differentiation Factor 15, a New Prognostic Marker in Diabetic Cardiomyopathy.
    Domínguez-Rodríguez A; Avanzas P; González-González J; Belleyo-Belkasem C; Abreu-González P
    Rev Esp Cardiol (Engl Ed); 2016 Jan; 69(1):81-3. PubMed ID: 26699098
    [No Abstract]   [Full Text] [Related]  

  • 2. Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus.
    Dominguez-Rodriguez A; Abreu-Gonzalez P; Avanzas P
    Am J Cardiol; 2014 Sep; 114(6):890-4. PubMed ID: 25073564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoadsorption can improve cardiac function in transplant candidates with non-ischemic dilated cardiomyopathy associated with diabetes mellitus.
    Dandel M; Englert A; Wallukat G; Riese A; Knosalla C; Stein J; Hetzer R
    Atheroscler Suppl; 2015 May; 18():124-33. PubMed ID: 25936316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A hypothesis: Glucagon-like peptide-1 may play a protective role in diabetic cardiomyopathy.
    Fan Z; Yang C; Yang J
    Int J Cardiol; 2015 Oct; 197():294-5. PubMed ID: 26142979
    [No Abstract]   [Full Text] [Related]  

  • 5. Growth Differentiation Factor-15 Level and Tissue Doppler Echocardiography as a Tool in Identification of Cardiac Effects in the Children with Type 1 Diabetes Mellitus.
    Uysal C; Arslan D; Buyukinan M; Gederet YT; Vatansev H; Ozcelik HS
    Exp Clin Endocrinol Diabetes; 2021 Aug; 129(8):574-580. PubMed ID: 31426113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy.
    Jellis CL; Sacre JW; Wright J; Jenkins C; Haluska B; Jeffriess L; Martin J; Marwick TH
    Eur Heart J Cardiovasc Imaging; 2014 Jul; 15(7):776-86. PubMed ID: 24472731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Serum Biomarkers in Early Detection of Diabetic Cardiomyopathy in the West Virginian Population.
    Shaver A; Nichols A; Thompson E; Mallick A; Payne K; Jones C; Manne ND; Sundaram S; Shapiro JI; Sodhi K
    Int J Med Sci; 2016; 13(3):161-8. PubMed ID: 26941576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes.
    Seferović Mitrović JP; Seferović PM; Vujisić Tešić B; Petrović M; Ristić AD; Lalić K; Jotić A; Tešić M; Giga V; Milić N; Singh S; Lalić NM
    Int J Cardiol; 2012 Apr; 156(2):219-21. PubMed ID: 22336253
    [No Abstract]   [Full Text] [Related]  

  • 9. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction.
    Izumiya Y; Hanatani S; Kimura Y; Takashio S; Yamamoto E; Kusaka H; Tokitsu T; Rokutanda T; Araki S; Tsujita K; Tanaka T; Yamamuro M; Kojima S; Tayama S; Kaikita K; Hokimoto S; Ogawa H
    Can J Cardiol; 2014 Mar; 30(3):338-44. PubMed ID: 24484911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic cardiomyopathy.
    Murarka S; Movahed MR
    J Card Fail; 2010 Dec; 16(12):971-9. PubMed ID: 21111987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
    Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetic cardiomyopathy: myth or reality?
    Ernande L; Derumeaux G
    Arch Cardiovasc Dis; 2012 Apr; 105(4):218-25. PubMed ID: 22633296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Wallentin L; Hijazi Z; Andersson U; Alexander JH; De Caterina R; Hanna M; Horowitz JD; Hylek EM; Lopes RD; Asberg S; Granger CB; Siegbahn A;
    Circulation; 2014 Nov; 130(21):1847-58. PubMed ID: 25294786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of growth-differentiation factor 15 to left ventricular remodeling in ST-segment elevation myocardial infarction.
    Dominguez-Rodriguez A; Abreu-Gonzalez P; Avanzas P
    Am J Cardiol; 2011 Oct; 108(7):955-8. PubMed ID: 21784389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth differentiation factor 15 in different stages of heart failure: potential screening implications.
    Wang F; Guo Y; Yu H; Zheng L; Mi L; Gao W
    Biomarkers; 2010 Dec; 15(8):671-6. PubMed ID: 20860541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression pattern of cardiovascular microRNAs in the human type-2 diabetic heart with normal ejection fraction.
    Rawal S; Ram TP; Coffey S; Williams MJ; Saxena P; Bunton RW; Galvin IF; Katare R
    Int J Cardiol; 2016 Jan; 202():40-3. PubMed ID: 26386917
    [No Abstract]   [Full Text] [Related]  

  • 18. Growth-differentiation Factor-15 and Tissue Doppler Imaging in Detection of Anthracycline-induced Cardiomyopathy During Therapy of Childhood Cancers.
    Kaya F; Arslan D; Vatansev H; Kose D; Cimen D; Akyurek F; Oran B; Koksal Y
    J Pediatr Hematol Oncol; 2016 Apr; 38(3):e107-12. PubMed ID: 26907646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.
    McCormick LM; Heck PM; Ring LS; Kydd AC; Clarke SJ; Hoole SP; Dutka DP
    Cardiovasc Diabetol; 2015 Aug; 14():102. PubMed ID: 26253538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic cardiomyopathy and diastolic heart failure -- difficulties with relaxation.
    Teupe C; Rosak C
    Diabetes Res Clin Pract; 2012 Aug; 97(2):185-94. PubMed ID: 22502812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.